Researchers have identified a blood biomarker that could help diagnose chronic traumatic encephalopathy in living patients, according to two preliminary studies published Thursday in the Journal of the American Medical Association. The neurodegenerative condition, commonly known as CTE, has long been linked to repetitive head impacts in contact sports such as American football, but it currently can only be definitively diagnosed through a post-mortem examination of brain tissue.
The research centers on a protein fragment called endogenously cleaved microtubule-binding region tau, or eMTBR-tau. While blood tests tracking this biomarker were initially created to detect abnormal tau tangles in patients with Alzheimer’s disease, investigators discovered that elevated levels of the fragment also correspond with severe stages of CTE, CBS News and Scientific American reported.
“This is a game changer,” Michael Alosco, co-director of clinical research at the Boston University CTE Center and an author on one of the studies, told reporters in a statement cited by CBS News. Alosco emphasized that while the research remains in its early phases, validated findings in larger trials could allow medical professionals to detect CTE with high accuracy and establish clinical treatment trials for living patients.
Identifying tau protein buildup
CTE occurs when repeated brain trauma causes tau proteins to misfold, tangle and aggregate inside nerve cells, disrupting brain function. In advanced stages, the disease can lead to severe memory loss, executive dysfunction, mood disturbances, depression and movement problems. Until now, physicians could only evaluate behavioral symptoms and rule out alternative causes without confirming the presence of CTE during a patient’s lifetime, according to the New York Post.
To differentiate CTE from Alzheimer’s disease—which also involves elevated tau levels—researchers noted that a second blood biomarker known as p-tau217 could be evaluated alongside eMTBR-tau. Scientific American reported that p-tau217 tracks closely with Alzheimer’s but does not elevate in CTE cases alone, potentially allowing a two-part blood screen to distinguish between the two neurodegenerative disorders.
Findings from two preliminary studies
One study, conducted by researchers at Boston University and Banner Health, evaluated blood samples taken during life from 21 former football players who agreed to donate their brains after death. Brain autopsies revealed that 18 of the 21 participants had CTE, including 16 who suffered from advanced stage 3 or stage 4 disease, according to the reports. Blood test results showed that eMTBR-tau concentrations were significantly higher in individuals with advanced CTE compared with those who had mild CTE or no disease.
The study included athletes from various competitive levels, Bleacher Report noted. Advanced CTE was diagnosed in 11 out of 12 former professional players, four out of seven college players, and one of two high school players. Participants who suffered from both CTE and Alzheimer’s disease demonstrated the highest overall concentrations of the tau biomarker.
A separate study led by researchers at Washington University in St. Louis examined stored blood samples from 11 individuals diagnosed with CTE after death. Co-author Chihiro Sato, an assistant professor of neurology at Washington University, stated that levels of eMTBR-tau243 were notably higher in patients with advanced CTE than in healthy controls, though the marker failed to reliably catch early-stage disease, Bleacher Report reported.
Challenges and validation ahead
Independent experts emphasized that the findings, while promising, represent an initial step toward clinical application. Dr. Rudolph Castellani, a neuropathologist at Northwestern University who was not involved in the research, cautioned to the Associated Press via Bleacher Report that the results remain preliminary and require confirmation through substantially larger trials.
In an accompanying editorial in JAMA, Drs. Günter Höglinger and Carla Palleis of Ludwig Maximilian University of Munich noted that tau protein accumulation in CTE differs structurally from Alzheimer’s. However, they described the combined studies as an important advance toward diagnosing living patients. The experimental blood test is not approved by the U.S. Food and Drug Administration, and researchers estimate that future validation studies will require hundreds of additional participants before clinical tests become available.



